All News

ASN Kidney Week 2026 experts discussed GLP-1 RAs alongside lifestyle care, global access, and bariatric surgery for obesity in chronic kidney disease.

Kidney Week 2026 abstracts show that AMKD progresses quickly in routine practice, with or without diabetes, despite background CKD therapy.

Insurance barriers were the top reason 4 in 10 people prescribed long-acting PrEP at a Missouri clinic never received it, an IDWeek 2026 poster found.

Samantha Pettigrew, MD, explains blood clot risk factors, treatment, and return to play in the wake of the news of Jalen Hurts season-ending diagnosis.

A retrospective study suggests strength exercise may be a safer option than endurance exercise for some people with ACM.

Infant flu protection from maternal vaccination varied by timing, while pediatric vaccination fell to 49.4%, experts report at IDWeek 2026.

The NCCN’s latest esophageal/EGJ guidance raises durvalumab plus FLOT to a category 2A recommendation for PD-L1–negative, diffuse-type disease.

Legal and clinical experts examined the US medical aid in dying framework, its limits, and ethical debates.

The pilot pairs grocery stipends and community health worker support with members who have unmanaged diabetes and unmet social needs.

Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.

Off-the-shelf CTX110 allogeneic CD19 CAR T shows responses in relapsed/refractory B-cell lymphoma, with manageable cytokine release syndrome.

The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.

ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.

A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.

AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.

IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.

An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.

Real-world data from CHEST 2026 show ETI improved lung function and BMI in children with CF aged 6 to 11, with the most gains in F508del homozygotes.

Birth centers are unavailable in 10 states, and 39% of birth center births are self-pay, as licensing and Medicaid pay limit access, a report finds.

Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.

Narcolepsy and idiopathic hypersomnia can go undiagnosed for years, and Epworth and RU-SATED screening help clinicians spot true sleepiness sooner.

FDA granted accelerated approval to dostarlimab-gxly for dMMR or MSI-H locally advanced rectal cancer based on interim phase 2 AZUR-1 results.

Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.

Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.

A review of 47 endometriosis guidelines found most came from high-income settings and diverged on biomarkers, repeat surgery, and fertility referral.

The meeting covered several topics in eye care, including how artificial intelligence (AI) can play a part in eye care.

A higher PNR is associated with lower odds of MASLD and advanced liver fibrosis, but further studies are needed to validate findings.

Speakers at CHEST 2026 walked through the first CHEST guideline for non-CF adult bronchiectasis, including which preventive therapy to start first.